1. Scrip
  2. >>Therapy Areas

Mallinckrodt's higher-dose PENNSAID OK'd in US for knee osteoarthritis pain

 
• By Donna Young

Shares of Mallinckrodt Pharmaceuticals gained as much as 5.1%, or $2.95, on 17 January on the news the FDA had approved the firm's topical nonsteroidal anti-inflammatory drug Pennsaid (diclofenac sodium topical solution) 2% as a treatment for pain of osteoarthritis of the knee.

Shares of Mallinckrodt Pharmaceuticals gained as much as 5.1%, or $2.95, on 17 January on the news the FDA had approved the firm's topical nonsteroidal anti-inflammatory drug Pennsaid (diclofenac sodium topical solution) 2% as a treatment for pain of osteoarthritis of the knee.

Pennsaid is supplied as a metered-dose pump bottle, which ensures the accurate amount of 20mg diclofenac is delivered per pump.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.